Yoland C. Antill, MD, on the Potential Role for Durvalumab in Treating Advanced Endometrial Cancer

Posted: Monday, June 10, 2019

Yoland C. Antill, MD, of Cabrini Health, discusses the potential role for the PD-L1 inhibitor durvalumab as monotherapy for recurrent or advanced endometrial cancer, based on phase II data from the PHAEDRA trial.